“Abdala is a vaccine that requires no freezing process to be preserved, unlike other vaccines, since it can be stored from four to eight degrees Celsius. It has been proved Abdala vaccine is thermostable for 15 days at 37oC without being affected.”

“It facilitates its distribution and a high vaccination coverage,” the CIGB tweeted.

CIGB highlighted that Abdala vaccine recently proved its safety, effectiveness to fight off the Covid-19 pandemic.

The Cuban Abdala vaccine is the first Covid-19 immunogen manufactured in Latin America and the Caribbean.

Since July 2021, the Cuban vaccine has been authorized for emergency use after proving 92.28% effectiveness in preventing symptomatic disease and 90% effectiveness in severe Covid-19 patients. It also showed a 99.15% rise in antibodies in volunteers aged three to 11 years and 98.28% in those aged 12 to 18 years.

The CIGB confirmed the increased antibody titers was fourfold or more from the first dose in these population groups.

Sonia Resik, senior researcher of the studies with this vaccine, praised that over 80% of adverse events reported in children were mild and the rest of indicators were comparable with data obtained in adults, ratifying its effectiveness.

Abdala vaccine, on the other hand, has maintained its safety, effectiveness and immune response to Covid-19, ratifying its suitability for booster doses.

Cuba also has produced Soberana 02 and Soberana Plus vaccines (from the Finlay Vaccine Institute) to fight the Covid-19 pandemic and two vaccine candidates (Soberana 01 and Mambisa) in clinical trials with important results.

pll/ro/joe